

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Molnupiravir for treating COVID-19 [ID6340]

Final Stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Merck Sharp & Dohme (molnupiravir) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Pulmonary Fibrosis • African Caribbean Leukaemia Trust • Anthony Nolan • Aplastic Anaemia Trust • Blood Cancer UK • Cancer52 • Cardiomyopathy UK • Cardiothoracic Transplant Patient Group • Chronic Lymphocytic Leukaemia Support Association • Chronic Myeloid Leukaemia Support Group • Clinically Vulnerable Families • Crohn's & Colitis UK • Diabetes UK • Down's Syndrome Association • Forgotten Lives UK • Immunodeficiency UK • Kidney Care UK • Kidney Research UK • Leukaemia Care • Leukaemia UK • Long Covid Kids • Long Covid Physio • Long Covid Scotland • Long COVID SOS • Long Covid Support • Lupus UK • Lymphoma Action • Macmillan Cancer Support • MDS UK Patient Support Group 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Government • Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> • Gilead Sciences (remdesivir) • GlaxoSmithKline (sotrovimab) • Pfizer (nirmatrelvir plus ritonavir) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Infectious Diseases Group • Cochrane UK • Genomics England • Institute of Cancer Research • Long Covid Research Initiative • MRC Clinical Trials Unit • National Institute for Health Research

Final Stakeholder list for the Single Technology Appraisal of molnupiravir for treating COVID-19 [ID6340]
Issue date: April 2024.

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Metabolic Support UK • MS Society • Multiple Sclerosis Trust • Myeloma UK • National Kidney Federation • National Rheumatoid Arthritis Society • Polycystic Kidney Disease Charity • Sarcoidosis UK • Scleroderma and Raynaud's UK • South Asian Health Foundation • Specialised Healthcare Alliance • Thrombosis UK • Vasculitis UK <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association for Clinical Biochemistry & Laboratory Medicine • Association of British Neurologists • Association of Cancer Physicians • British Geriatrics Society • British HIV Association • British Infection Association • British Paediatric Allergy Infection and Immunity Group • British Society for Allergy & Clinical Immunology • British Society for Heart Failure • British Society for Immunology • British Society for Rheumatology • British Thoracic Society • British Transplant Society • Cancer Research UK • Faculty of Pharmaceutical Medicine • Infection Prevention Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for General Microbiology • UK Clinical Pharmacy Association • UK CLL Forum • UK Kidney Association • UK Renal Pharmacy Group 	<p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

Consultees	Commentators (no right to submit or appeal)
<p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS North East and North Cumbria ICB • NHS South East London ICB 	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Draft Guidance..

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Draft Guidance.

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the Final Draft Guidance for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.

All non-company commentators are invited to nominate clinical specialists or patient experts.